REDPINE

REDPINE's product line includes single-use video endoscopes such as ureteroscopes, cystoscopes, and hysteroscopes, which are designed for mass production. These devices are complemented by a reusable Endoscopic Video Image Processor, compatible with multiple types of scopes. The company has developed core technologies in medical optics and image processing, featuring an ultra-clear imaging engine (SHIE) and auxiliary diagnostic tools like enhanced border imaging (EBI) to help physicians detect lesions. This focus on image quality aims to rival that of reusable scopes while maintaining the cost and safety benefits of a single-use model.

Since its inception, REDPINE has achieved significant milestones, including receiving Angel investment in 2017 and completing multiple rounds of venture capital financing, with Series A in 2020, Series B in 2021, and Series C in 2022. The company has secured regulatory approvals for its products, including CE certification in Europe and 510(k) clearance from the FDA in the United States, facilitating its expansion into international markets. REDPINE has established a global presence, with its products used in Europe, North America, Asia, and the Middle East, and actively participates in international medical conferences to showcase its technology. The company operates out of a GMP-certified factory and has built automated production lines to support a production capacity of over one million units annually.